Oltmans Curtis Gale 4
4 · ARRAY BIOPHARMA INC · Filed Feb 7, 2019
Insider Transaction Report
Form 4
Oltmans Curtis Gale
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2019-01-29$8.94/sh+11,100$99,234→ 15,021 total - Exercise/Conversion
Common Stock
2019-02-05$8.94/sh+40,000$357,600→ 55,021 total - Sale
Common Stock
2019-02-05$20.00/sh−40,000$800,000→ 15,021 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-02-05−40,000→ 363,900 totalExercise: $8.94Exp: 2027-08-15→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]These trades were made pursuant to a Rule 10b5-1 trading plan.
- [F2]The option vests in four equal annual installments beginning August 15, 2018.